CTOs on the Move

Provation Medical

www.provationmedical.com

 
Provation is a leading provider of clinical productivity software for healthcare professionals, with solutions for intelligent procedure documentation (Provation® MD and Provation® Apex), order set and care plan management (Provation® Order Sets and Provation® Care Plans), and EHR-embedded clinical documentation templates (Provation® Clinic Note). Our software helps providers increase operational efficiencies, business profitability and regulatory compliance by improving quality, streamlining workflows and enabling the generation of insights. Trusted by leading physicians globally, we serve approximately 1,500 hospitals and 1,000 ambulatory surgery centers (ASCs), including 16 of the top 20 U.S. hospitals for gastroenterology (GI) and GI surgery. Provation is headquartered ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details
Linda Buan
 Chief Technology Officer Profile

Similar Companies

Qspex Technologies

QSpex embodies the ideal to provide its capital partners best-in-class financial returns, and its customers distinguishable and meaningful value. We will deliver on these fundamentals, while delivering on a higher purpose, advancing the eco-system at-large. We will do this through an inspired vision, integrated ideals, an accountable organization and compassionate leadership.

Laurel Health System

Laurel Health System is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Laurel Health System is based in Wellsboro, PA. You can find more information on Laurel Health System at www.laurelhs.org

Valley Counseling Group

Valley Counseling Group is a Bethlehem, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nurses Choice Corp

Nurses Choice Corp is a Wilmington, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Metamark

Metamark Genetics, Inc. is a privately held biotechnology company founded in 2007 to develop novel, function-based, prognostic and diagnostic tests aimed at improving cancer care. The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, colon, and breast cancers. In early 2014, Metamark plans to commercialize ProMark™—its prostate cancer prognostic test—through its Cambridge, Massachusetts CLIA-certified laboratory. For more information, please visit the company's Website at www.metamarkgenetics.com. Metamark™ and ProMark™ are trademarks of Metamark Genetics, Inc.